NARDIL

This brand name is authorized in Australia, Canada, Estonia, Netherlands, New Zealand, United States

Active ingredients

The drug NARDIL contains one active pharmaceutical ingredient (API):

1 Phenelzine UNII 2681D7P965 - PHENELZINE SULFATE

Phenelzine is an irreversible non-selective inhibitor of monoamine oxidase. Although the exact mechanism of action has not been determined, it appears that the irreversible, nonselective inhibition of MAO by phenelzine relieves depressive symptoms by causing an increase in the levels of serotonin, norepinephrine, and dopamine in the neuron. Phenelzine is used for the treatment of major depressive disorder. Has also been used with some success in the management of bulimia nervosa. Read about Phenelzine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
NARDIL Film coated tablet	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N06AF03	Phenelzine	N Nervous system → N06 Psychoanaleptics → N06A Antidepressants → N06AF Monoamine oxidase inhibitors, non-selective
Discover more medicines within N06AF03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 2856H
Country: CA	Health Products and Food Branch	Identifier(s): 00476552
Country: EE	Ravimiamet	Identifier(s): 1711640
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 51314
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 11157
Country: US	FDA, National Drug Code	Identifier(s): 0071-0350